Trial
NCT06333522
Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty
Phase IVWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
—
Condition
Arthrofibrosis of Knee
Intervention
Losartan
Why stopped
Study team unable to identify method for approval of the medication as standard of care and compounded.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-23